US 12,070,471 B2
Remote loading of sparingly water-soluble drugs into lipid vesicles
Mark E Hayes, San Francisco, CA (US); Charles O. Noble, San Francisco, CA (US); and Francis C. Szoka, San Francisco, CA (US)
Assigned to CELATOR PHARMACEUTICALS, INC., Palo Alto, CA (US)
Filed by CELATOR PHARMACEUTICALS, INC., Palo Alto, CA (US)
Filed on Feb. 17, 2023, as Appl. No. 18/170,704.
Application 18/170,704 is a continuation of application No. 16/726,624, filed on Dec. 24, 2019, granted, now 11,583,544.
Application 16/726,624 is a continuation of application No. 15/972,012, filed on May 4, 2018, abandoned.
Application 15/972,012 is a continuation of application No. 15/502,092, granted, now 10,004,759, issued on Jun. 26, 2018, previously published as PCT/US2015/043594, filed on Aug. 4, 2015.
Claims priority of provisional application 62/033,073, filed on Aug. 4, 2014.
Prior Publication US 2023/0390317 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7048 (2006.01); A61K 9/127 (2006.01); A61K 9/19 (2006.01); A61K 31/337 (2006.01); A61K 31/395 (2006.01); A61K 31/4196 (2006.01); A61K 31/496 (2006.01); A61K 31/704 (2006.01); A61K 38/07 (2006.01); A61K 47/02 (2006.01)
CPC A61K 31/7048 (2013.01) [A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 9/1277 (2013.01); A61K 9/19 (2013.01); A61K 31/337 (2013.01); A61K 31/395 (2013.01); A61K 31/4196 (2013.01); A61K 31/496 (2013.01); A61K 31/704 (2013.01); A61K 38/07 (2013.01); A61K 47/02 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A pharmaceutical formulation comprising a liposome suspended in a pharmaceutically acceptable carrier, the formulation comprising:
(a) a lipid fraction comprising sphingomyelin forming the liposome, the liposome encapsulating an internal aqueous medium comprising a solid precipitate of a salt of a sparingly water-soluble agent having a water solubility of less than about 2 mg/mL, wherein the liposome is free of a solubilizing agent for the sparingly water-soluble agent; and
(b) the pharmaceutically acceptable carrier.